WAVE Life Sciences Ltd (NASDAQ:WVE) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

For the most recent quarter, Wave Life Sciences reported -$0.25 earnings per share (EPS), missing the consensus estimate of ...

According to a post on the FDA’s website, Wave Life Sciences (WVE)’ treatment of Huntington’s disease received orphan ...

Wave Life Sciences (NASDAQ:WVE – Get Free Report) had its price objective increased by research analysts at B. Riley from $19.00 to $22.00 in a note issued to investors on Monday, Benzinga reports.

B. Riley raised the firm’s price target on Wave Life Sciences (WVE) to $22 from $19 and keeps a Buy rating on the shares following the ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Wave Life Sciences (WVE) reports results for the quarter ended September 2024. While this widely-known consensus outlook ...

PLANS TO HAVE FIVE GALNAC-RNA EDITING OR GALNAC-SIRNA PROGRAMS IN CLINIC BY 2026 * WAVE LIFE SCIENCES LTD: WVE-007 (INHBE GALNAC-SIRNA FOR OBESITY) IS ON TRACK TO INITIATE A CLINICAL TRIAL IN 1Q 2025 ...

Biotech startup Evommune, an early tenant of the Kips Bay life sciences incubator known as Cure, raised $115 million in a ...

Wave Life Sciences Ltd. (NASDAQ: WVE) is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. The company is generating ...